Scavenger receptor class B type I (SR-BI) is the high-affinity high-density lipoprotein (HDL) receptor, and CLA-1 is the human homologue of the murine SR-BI. CLA-1/SR-BI receptor has been suggested as a new preventative and/or therapeutic target for atherosclerosis due to its pivotal role in overall HDL cholesterol (HDL-C) metabolism and its antiatherogenic activity in vivo. To search for active compounds that can increase CLA-1 transcription, a novel cell-based assay was developed for application in high-throughput screening (HTS). Human hepatoma HepG2 cells were transfected with a CLA-1-promoter-luciferase reporter gene construct, and the stable transfected cell line was selected and named CLAp-LUC HepG2. With rosiglitazone as a positive control, this stable cell line was used to establish a specific CLA-1 gene expression assay in a 96-well microplate format. The evaluating parameter Z´ value of 0.64 showed that this cell-based HTS assay was robust and reliable. Screening of 6000 microbial secondary metabolite crude extracts identified 8 positive strains. Between 2 identified CLA-1 up-regulators produced by actinomycete strain 04-4776, 4776B may stimulate not only the expression of CLA-1 on the transcriptional and translational levels but also the activity of CLA-1 to uptake the HDL-C in HepG2 cells. The active compounds originated from this HTS assay may be developed to drug candidates or lead compounds for new antiatherosclerosis agents. (Journal of Biomolecular Screening 2007:211-219) 
INTRODUCTION
P LASMA LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLES-TEROL (HDL-C) are inversely associated with the risk of atherosclerotic cardiovascular disease. The protective effect of HDL may be mediated by its role in reverse cholesterol transport (RCT), whereby plasma cholesteryl ester (CE) is transported to the liver for secretion. 1 Scavenger receptor class B type I (SR-BI) is the first high-affinity HDL receptor to be identified at the molecular level, 2 and the CLA-1 (CD36 and Lysosomal integral membrane protein-II Analogous-1) gene 3 is the human homologue of the murine SR-BI gene (hSR-BI). The CLA-1/SR-BI receptor is abundantly expressed mainly in the liver, 4 where it mediates selective uptake of cholesteryl ester from HDL. It is also expressed in macrophages and can promote cholesterol efflux to HDL in vitro. 5 Furthermore, hepatic SR-BI expression could positively regulate the rate of macrophage RCT in vivo. 6 So CLA-1/SR-BI plays a pivotal role both in the initial (HDL-C efflux and removal from the artery wall) and final (selective HDL-C uptake in the liver) phase of RCT. The importance of SR-BI in overall HDL-C metabolism and its antiatherogenic activity in vivo has been definitely established by SR-BI gene manipulation in mice (see Trigatti et al. 7 and references therein), and CLA-1/SR-BI receptor has been suggested as a new preventative and/or therapeutic target for atherosclerosis. 8 Although the significance of CLA-1 in human HDL metabolism and atherosclerosis has yet to be well explored, the recent identification of mutations/polymorphisms in CLA-1 and their association with altered HDL and non-HDL cholesterol levels 9, 10 and with coronary heart disease (CHD) risk 11 suggest that CLA-1 plays an equally important role in lipid transport in normal physiology and pathological conditions in humans. The discovery of upregulators of CLA-1 expression may benefit the further study of the function of CLA-1 in human atherosclerotic cardiovascular diseases and might have pharmacologic applications.
To obtain new active compounds that can increase CLA-1 transcription level in liver cells, we developed a cell-based reporter assay applicable for high-throughput screening (HTS). In this assay, we used the human hepatoma cell line HepG2 cells stably transfected with pGL3-CLAP, 12 in which a firefly luciferase reporter gene was fused downstream of the 5´-flanking promoter region of the human CLA-1 gene. 4 Rosiglitazone, a specific peroxisome proliferators-activated receptor γ (PPARγ) agonist, which may stimulate the expression of human hepatic SR-BI transcription, 13 was used as a positive control for optimization and evaluation of the HTS assay for detection in a multiwell format. As microbial secondary metabolites are important resources of bioactive molecules, especially for structurally and mechanistically new molecules serving as useful direct drugs or lead compounds, 14 we screened a proprietary microbial secondary metabolite crude extract library using the developed cell-based assay, and several positive strains have been detected. Herein we describe the identification of 2 putative CLA-1 upregulators produced by strain 04-4776, one of which not only may stimulate the expression of CLA-1 on transcriptional and translational levels but also the activity of CLA-1 to uptake the HDL-C in HepG2 cells. Thus, the screening and validation approach presented here offers a robust method for the discovery of novel CLA-1 up-regulators.
MATERIALS AND METHODS

Materials
1,1´-Dioctadecyl-3,3,3´,3´-tetramethylindocarbocyanine perchlorate-labeled HDL (DiI-HDL) was purchased from Biomedical Technologies (Stoughton, MA). White-wall, clearbottom 96-well polystyrene assay plates were obtained from BMG LABTECH (Offenburg, Germany); 60-mm dishes and 24-and 96-well plates for cell culture were obtained from Corning (Corning, Acton, MA). Cell culture media and fetal bovine serum (FBS) were from Hyclone (Logan, UT). G418 was obtained from Invitrogen (Carlsbad, CA).
Preparation of screening sample libraries
The microorganism strains from the China Center of Medicinal Culture Collection (Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China) were cultured at 28 °C for 4 days in medium I for actinomycetes (glucose 0.5%, yeast extract 0.5%, peptone 0.5%, beef extract 0.5%, corn steep liquor 0.4%, soybean powder 1%, starch 2%, CaCO 3 0.4%, CoCl 2 0.0004 mg/L [pH 7.2]) and medium II for fungi (malt extract 2%, K 2 HPO 4 0.05%, vitamin B 1 µg/100 mL, yeast extract 0.5%, glucose 2%, MgSO 4 0.03%, peptone 1%, corn steep liquor 0.1% [pH 6.0]). Then, 10 mL of the mixtures of mycelia and fermentation broth was soaked in 10 mL of acetone for 1 day and then centrifuged. The 15-mL supernatant was concentrated in vacuo to dryness, dissolved in 1 mL of DMSO, and stored at 4 °C. The samples from the microbial secondary metabolite crude extract library were diluted 1000 times from stock solutions before being used in HTS screening.
Cell culture and selection of stable transfected cell line
HepG2 human hepatoma cells were grown in minimum essential medium with Earle's balanced salt and 2 mM L-Glutamine solution (medium A) supplemented with 10% FBS (medium B) at 37 °C in a humidified 5% CO 2 incubator.
HepG2 cells were cotransfected with pGL3-CLAP, 12 a construct containing human CLA-1 promoter region (-1055 to -62 bp; nucleotide +1 corresponds to the A of the ATG start codon 4 ), and pcDNA3 (Invitrogen, Carlsbad, CA) at 90% confluence using the Lipofectamine™ 2000 (Invitrogen) following the manufacturer's instructions. Then cells were trypsinized, and a serial dilution in medium B was performed following 24 h of incubation. Selection of stable transfected cells was carried out by treatment with G418 (700 µg/mL) in 96-well culture plates. After 14 days under the selection pressure, single-cell clones with drug resistance were chosen, and the expressed luciferase activity of different clones was measured using the Luciferase Assay System (Promega, Madison, WI). A stably transformed clone that presented a normal cell cycle and highest expression level was designated CLAp-LUC HepG2. This cell line was maintained in medium C (medium B supplemented with 600 µg/mL G418).
Reporter assay using CLAp-LUC HepG2 cells
The CLAp-LUC HepG2 cells were seeded in 96-well plates at an indicated cell number/well in 100 µL medium C. After incubation, the cells at 80% confluence were washed once with PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 [pH 7.3]), followed by refeeding with 200 µL medium A containing the indicated concentrations of negative control (DMSO), positive control, or screening samples. After the indicated time of incubation at 37 °C, cells were washed with PBS, and then the luciferase activity was detected as relative luminescence units (RLUs) using the Luciferase Assay System (Promega).
Fermentation of actinomycete 04-4776
Actinomycete 04-4776 was inoculated into a 250-mL flask containing 50 mL of medium I and incubated for 4 days at 28 °C on a rotary shaker (220 rpm). Then, 5 mL of the first seed culture was transferred to a 500-mL flask containing 100 mL of medium I and incubated for 2 days at 28 °C on a rotary shaker (220 rpm). Of the second seed culture, 100 mL was inoculated into a 5000-mL flask containing 900 mL of medium I and incubated on a rotary shaker (220 rpm) at 28 °C for 4 days.
Isolation, purification, and structure elucidation of 4776B and 4776C
The fermentation broth (3 × 20 L) was centrifuged at 5000 rpm for 20 min. The supernatants and the concentrated solution of acetone extract of mycelia were passed through a 6 × 40-cm column of HP20 macroporous resin (Mitsubishi Chemical, Tokyo, Japan), which was eluted with water, 20% acetone/water, 50% acetone/water, 80% acetone/water, and 100% acetone. The 80% acetone/water fraction containing CLA-1 up-regulator activity was concentrated to dryness, subjected to a 2 × 100-cm column of the Sephadex LH-20 (GE Healthcare, Piscataway, NJ), and eluted with 2 bed volume of 60% MeOH/water, 80% MeOH/water, and 100% MeOH, respectively. The eluates were monitored by analytical high-performance liquid chromatography (HPLC), and the fractions containing CLA-1 up-regulator activity were combined and concentrated to dryness for further purification. The pure active compounds 4776B and 4776C were obtained by purification with semipreparative HPLC (Shim-pack PREP-ODS, 20 × 390 mm, Shimadzu, Kyoto, Japan), which was eluted isocratically with 40% acetonitrile/water. The physicochemical properties of 4776B and 4776C were determined via UV spectrometer (UV-200S, Shimadzu), mass spectrometer (JMS-DX 300, Jeol, Tokyo, Japan), and nuclear magnetic resonance (NMR) spectrometer (XL-400, Varian, Palo Alto, CA). The structure of 4776B was elucidated by means of spectral data of UV, IR, EI-MS, ESI-MS, 1 H-NMR, 13 C-NMR, HSQC, HMBC, and NOESY with CD 3 OD and CD 3 COCD 3 as the solvents. The structure of 4776C was determined by means of spectral data of UV, IR, EI-MS, ESI-MS, 1 H-NMR, 13 C-NMR, 1 H-1 H COSY, DEPT, HSQC, and HMBC.
RNA isolation and analysis of transcript level
Relative quantification of CLA-1 mRNA was assessed by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). HepG2 cells were plated in a 60-mm dish in medium B at 500,000 cells/dish. After 24 h of incubation at 37 °C, cells were washed twice with cold PBS and then refed with medium A containing the designated concentrations of compound 4776B or 4776C. Total cellular RNA was isolated using Trizol reagent (Invitrogen) and analyzed by agarose gel electrophoresis to check that ribosomal RNAs were intact. RNA samples (4 µg) were reverse transcribed using ThermoScript™ RT (Invitrogen) and primer Oligo(dT) 20 (Invitrogen) at 55 °C for 60 min. After heating the reaction at 85 °C for 5 min, one tenth of the reverse transcription reaction was used for PCR to amplify the CLA-1 transcripts, using human glyseraldehyde-3phosphate dehydrogenase (GAPDH) as an internal control. The primer pairs used for the amplification of CLA-1 mRNA (672 bp) and human GAPDH mRNA (452 bp) were as described in Huang et al. 15 The number of amplification cycles was optimized to guarantee the measurements within a linear range. 16 PCR was performed for 25 (CLA-1) and 20 (GAPDH) cycles following an initial denaturation for 5 min at 94 °C. Each cycle consisted of denaturation at 94 °C for 1 min, primer annealing at 60 °C for 30 sec, and primer extension at 72 °C for 1 min. A final 10-min extension step at 72 °C was performed. Then, 5 µL of each PCR reaction were electrophoresed on 1.0% agarose gels. The amplified CLA-1 DNA bands were quantified using a video-densitometric scanner (ChemiImager 5500, Alpha Innotech, San Leandro, CA) and normalized to the intensity of amplified GAPDH DNA bands.
Western blot analysis
For Western blot, the pretreatment of HepG2 cells was the same as that for transcript analysis. After 24 h of incubation at 37 °C, cells were washed twice with PBS prior to the lysis in 200-µL/well lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% NP-40, 0.1% SDS). Protein extracts (30 µg) from control and treated cells were subjected to 12% SDS-polyacrylamide gel electrophoresis. Proteins were then transferred to a 0.45-µm polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA). Transfer of the proteins to the membrane was inspected by nonpermanent staining with Ponceau S (0.5% Ponceau S in 1% acetic acid). Then the membrane was blocked for 1 h at room temperature in PBS containing 0.1% Tween-20 (PBST) in the presence of 5% nonfat dry milk. Membranes were incubated overnight with a mouse monoclonal antibody against CLA-1 (BD Biosciences, San Jose, CA) in PBST with 1% BSA, followed by incubation with horseradish peroxidase (HRP)-conjugated goat antimouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature, and detection was achieved using an enhanced chemiluminiscence (ECL) detection system (Santa Cruz Biotechnology) and quantified using ChemiImager 5500 (Alpha Innotech). Human β-actin was similarly detected as an internal control to normalize the intensity of the immunoreactive CLA-1 bands.
Flow cytometry analysis for uptake of DiI-labeled HDL
HepG2 cells were plated in 24-well dishes at 50,000 cells/well, followed by treatment for about 18 h with compound 4776B or 4776C, as previously described, and then incubated with DiI-HDL (2 µg/mL) for 4 h at 37 °C. Cells were then washed with PBS and incubated with PBS containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA for 1 h at 4 °C, detached from the plate by gentle pipetting. The cell suspension was centrifuged (3 min, 800 g, 4 °C), the obtained pellet was resuspended in PBS, and DiI fluorescence was analyzed using an Epics XL flow cytometer (Coulter Corporation, Miami, FL).
HTS assay performance and data analysis
To assess the robustness of the HTS assay, the Z´ value was calculated as described in Zhang et al. 17 Positive (10 µM Novel Human High-Density Lipoprotein Receptor Up-regulators rosiglitazone) and negative (0.1% DMSO) controls were included in each 96-well plate for screening, and the regulatory activity of tested samples was defined as (RLU test compound /RLU negative control ) × 100%. The sample was identified as a primary hit when its tested regulatory activity was ≥ 150%. For validation of the screening results, tested samples identified as hits in HTS were reassayed in triplicate, and a "validated hit" was defined as a sample for which reassay showed ≥ 150% regulative activity at a 95% confidence interval. Apparent EC 50 values were calculated using OriginPro 7.5 (OriginLab, Northampton, MA).
All experiments except the primary HTS screening were repeated at least 3 times, and representative results are presented. Quantitative data are expressed as mean ± SE. Statistical significance of the data was evaluated by Student t-test. Probability values p < 0.05 were considered significant.
RESULTS
Cell-based assay for CLA-1 up-regulators
A previously described reporter construct, pGL3-CLAP, 12 was used to generate HepG2 cell lines stably expressing luciferase under the control of the CLA-1 promoter region (-1055 to -62 bp; nucleotide +1 corresponds to the A of the ATG start codon 4 ). Stable transformed cell lines expressing high luciferase activity were selected after 20 generations, and the highest active cell line, designated CLAp-LUC HepG2, was characterized further using rosiglitazone, one of the specific PPARγ agonists that have been reported as stimulators of the hepatic transcription of CLA-1. 13 Stimulation of the CLA-1 promoter mediated by rosiglitazone was detected by changes of luciferase activity in CLAp-LUC HepG2 cells. From the concentration of 0.1 to 25 µM, rosiglitazone up-regulated the promoter activity in CLAp-LUC HepG2 cells in a dose-dependent manner. The measured EC 50 value was 1.05 µM, reaching maximal up-regulation at about 10 µM (Fig. 1) .
In the development of the assay for the detection of CLA-1 up-regulators, CLAp-LUC HepG2 cells were used in the following screening application, using 10 µM rosiglitazone as a positive control. The assay was established using a 96-well format, and the optimization was focused on the concentration of DMSO, incubation time, and cell number/well. A series of optimizations led to the following optimal screening conditions:
1.
DMSO concentration: 0.1% ( Fig. 2A) 
2.
Incubation time: 18 h (Fig. 2B) 
3.
Cell number: 50,000 cells/well (Fig. 2C) DMSO sensitivity experiments showed that the assay can tolerate up to 0.5% DMSO, with no apparent loss in luciferase activity and cell viability. Exceeding 1% DMSO produced significant lower luciferase activity and higher cytotoxicity. The assay performance was quantitatively assessed using a Z´ factor based on the optimized conditions defined above. The Z´ factor value of this developed cell-based assay for CLA-1 up-regulators was 0.64.
HTS analysis of microbial crude extract library
Six thousand crude extracts from the microbial secondary metabolite crude extract library were screened using the developed cell-based assay. Of 14 primary hits (≥ 150% regulatory activity), 8 crude extracts of microbial secondary metabolites were confirmed to be validated hits. The positive rate of this screening assay reached about 1.3%. Positive microorganism strains, such as 04-4776, 04-9179, and 04-9007, belong to actinomycetes and fungi according to primary identification mainly based on the morphological characteristics. Actinomycete strain 04-4776 was chosen as representative for further isolation and characterization of active compounds.
Purification and structure identification of active compounds
The tertiary fermentation broth of actinomycete strain 04-4776 was used to isolate active compounds that might increase the luciferase activity of CLAp-LUC HepG2 cells. After purification by column chromatography of HP20 macroporous resin, LH-20 sephadex gel filtration, and semipreparative HPLC, 2 pure compounds-4776B and 4776C (> 95% purity)-were isolated from the fermentation broth of positive strain 04-4776, producing CLA-1 up-regulator(s). The physicochemical properties of 4776B and 4776C were determined (data not shown), and their structures were identified as 4´-methoxyl-3´,5, 7-hydroxyl isoflavone (Fig. 3A) and (9R,13S)-7-deoxy-13dihydrodaunomycinone ( Fig. 4A) by means of analyzing various spectral data, respectively. The dose-response curves for 4776B and 4776C on increasing luciferase activity of CLAp-LUC HepG2 cells were detected using the developed assay ( Figs. 3B, 4B ). 4776B and 4776C both increased the luciferase activity of CLAp-LUC HepG2 cells in a dose-dependent manner, and the measured EC 50 values were 1.08 µM and 1.14 µM, respectively. The maximal CLA-1 up-regulatory activity of 4776B reached 186% at about 2.08 µM (Fig. 3B) , whereas that of 4776C reached 213% at about 6.51 µM (Fig. 4B) .
Characterization of 4776B and 4776C on CLA-1 expression
To confirm the CLA-1 up-regulatory activity of 4776B and 4776C identified in the developed HTS based on the luciferase reporter assay, we further characterized them in several different assays. First, semiquantitative RT-PCR was performed to investigate the abundance of CLA-1 mRNA in 4776B-and 4776C-treated HepG2 cells. Both 4776B and 4776C stimulated CLA-1 expression at a transcriptional level in HepG2 cells at the concentration that showed maximal activity in the luciferase reporter assay. CLA-1 mRNA abundance increased to 4.52-fold after 4776B treatment at 2.08 µM, whereas 4776C showed similar stimulation (4.47-fold) at 6.51 µM (Fig. 5A) . Second, the CLA-1 protein level was tested in 4776B-and 4776C-treated HepG2 cells. At the same concentration tested above, the protein expression level of CLA-1 increased 95% and 83% by 4776B and 4776C, respectively (Fig. 5B) . Last, the effect of 4776B and 4776C on uptake of fluorescence-labeled HDL (DiI-HDL) in HepG2 cells was determined by flow cytometry analysis. Of 4776B, 2.08 µM promoted the uptake of DiI-HDL into the HepG2 cells by 25% (Fig. 5C) . As for 4776C, no stimulative effect was detected at the concentration of 6.51 µM (data not shown).
DISCUSSION
Current pharmacologic treatment for atherosclerotic heart disease consists mainly of the administration of HMG-CoA reductase inhibitors, called statin drugs, to reduce low-density lipoprotein cholesterol (LDL-C) concentrations. However, statins reduce cardiovascular events by only about 20% to 40%. 18 This has led to increased interest in targeting other lipid-related risk factors for cardiovascular disease, and an antiatherogenic strategy focusing on HDL represents a new frontier in the management of atherosclerosis. 19 A novel hepatic receptor, CLA-1/SR-BI, has been identified that is responsible for hepatic HDL-associated cholesterol uptake independent of the classic LDL pathway. The enhancement of CLA-1/SR-BI expression and/or its activity represents a significantly potential strategy to promote reverse cholesterol transport and inhibit atherosclerosis. 8, 19 CLA-1/SR-BI may facilitate both efflux of cholesterol from peripheral cells (such as macrophage foam cells in the arterial wall) and selective uptake of cholesterol in the liver (the key organ in regulating the metabolism of cholesterol), the initial and final steps of RCT. However, studies have suggested that CLA-1/SR-BI expression in the liver is especially important for HDL metabolism and overall cholesterol homeostasis in vivo. 7 Furthermore, the hepatic expression of SR-BI was demonstrated as a positive regulator of macrophage RCT in vivo, 6 so a human hepatocyte cell line (HepG2) was used to develop the cell-based HTS assay for the discovery of up-regulators of CLA-1 transcription in the present work.
CLA-1/SR-BI is abundantly expressed in several tissues, including the liver, where its expression is regulated by various mechanisms, including dietary, hormonal, metabolic, and pharmacological manipulations. 20 The promoter sequences of both human and murine SR-BI genes already have been determined 4, 21 and are very GC rich, with several important transcriptional regulatory sites in this region. Although the detailed molecular mechanism(s) has yet to be investigated, some recent studies have indicated the important roles of transcription factors and nuclear receptors in the regulation of hepatic CLA-1/SR-BI expression. Treguier et al. 22 established that the promoter region of CLA-1/SR-BI is transactivated by transcription factor sterol regulatory element binding protein 2 (SREBP-2), a key regulator of cellular cholesterol homeostasis. A functional SRE (-288 to -297 bp; nucleotide +1 corresponds to the A of the CLA-1 ATG start codon, the same as below) was identified in the promoter region of CLA-1, adjacent to a functional general transcription factor Sp1-binding site. 22 An 11-bp deletion corresponding to the Sp1-binding site in the CLA-1 gene has been identified in a Taiwanese Chinese population, and this genetic variant in the promoter region of CLA-1 could significantly influence the interindividual variation of plasma HDL-C levels in humans. 10 Schoonjans et al. 23 identified CLA-1/SR-BI as a target gene of liver receptor homolog 1 (LRH-1) in liver, and LRH-1 stimulates CLA-1/SR-BI expression through a unique LRH-1 regulatory element (-204 to -224 bp). Malerod et al. 13 found that hepatic CLA-1/SR-BI was a PPARγ target gene in rats, mice, and humans, and the PPARγ responding region was mapped within the -459 to -472 bp of the 5´ flanking region of CLA-1 gene. More in vivo and in vitro studies have reported that the expression of CLA-1/SR-BI in the liver is also regulated by the pregnane X receptor (PXR), 24 farnesoid X receptor (FXR), 25 liver X receptor (LXR), 26 and heptocyte nuclear factor 4α (HNF4α). 13 In this work, a firefly luciferase reporter gene construct under the control of the CLA-1 gene promoter containing several cisacting regulatory elements located within the 5´-flanking region (-1055 to -62 bp) 12 was used for the establishment of the HTS assay.
Although transient transfection of reporter gene construct pGL3-CLAP into hepatoma cells can provide similar information, 12 the experimental process is more time-consuming and labor intensive, and the data can be significantly more variable. So the stably transfected cell-based assays were developed in the present work by generation and selection of a HepG2 cell line stably expressing luciferase. Thiazolidinediones (TZDs, with rosiglitazone as a paradigm), specific PPARγ agonists, were used in the treatment of type 2 diabetes, and these agents were also reported to protect against the development of atherosclerosis. 27 In the developed assay, rosiglitazone may stimulate the luciferase activity in CLAp-LUC HepG2 cells ( Fig. 1) , which is in accordance with the results of Malerod et al. 13 This result confirmed the validity of using CLAp-LUC HepG2 cells for measuring activity of CLA-1 up-regulators. Thus, rosiglitazone was used as a positive control in the optimization of the HTS assay for CLA-1 upregulators. After several assay parameters (DMSO concentration, incubation time, cell number/well, etc.) were defined, this assay resulted in high confidence in the ability to detect compounds with CLA-1 up-regulatory activity, as reflected by the excellent Z´ value (0.64) in an HTS configuration.
Application of this assay in screening the microbial secondary metabolite crude extract library resulted in 8 positive strains. The hit definition used in this assay was chosen to limit hits to those microbial secondary metabolites with relatively high activity (i.e., regulatory activity ≥ 150%). Screening and identification of active compounds from microbial secondary metabolites further validated the screening assay developed in the present study. Both positive compounds 4776B and 4776C significantly influenced CLA-1 transcriptional activity at low micromolar concentrations in the developed assay (the EC 50 concentration for 4776B and 4776C was 1.08 µM and 1.14 µM, reaching maximal upregulation at about 2.08 µM and 6.51 µM, respectively), and the up-regulatory activity was demonstrated at the transcriptional level by semiquantitative RT-PCR and at the protein level by Western blot in the treated HepG2 cells. Furthermore, 4776B could also increase the uptake of DiI-labeled HDL by the treated HepG2 cells, whereas 4776C did not show a significant difference in treated and nontreated cells. This result indicated that, except for the up-regulation of CLA-1 transcription, active compounds might also influence different posttranslational regulation of CLA-1-for example, the topological structure, glycosylation degree, modification of extracellular and cytoplasmic domain, and so on, 28, 29 all of which may contribute to the protein function.
Another possible explanation for this result is that 4776C might also influence other cellular target(s) that regulate the HDL-C uptake in HepG2 cells. Interestingly, the active compound 4776B was identified as belonging to isoflavones, a family of compounds previously postulated as natural products that may be beneficial to postmenopausal women in cardiovascular health. 30, 31 The chemical structure of 4776B was identified as pratensein, which is one of the isoflavone contents in the leguminous plant Trifolium pratense L. The previous study demonstrated that pratensein displayed hypolipidemic activity in Triton-WR1339-induced hyperlipidemia in male albino rats. 32 The present data showed that 4776B up-regulates CLA-1 expression and activity in HepG2 cells, which might provide another possible mechanism for the antiatherosclerosis activity of isoflavones.
Two active compounds with distinctive chemical structures were identified from the crude extract of strain 04-4776 in this work. Different active compound(s) have also been isolated and identified from positive strains 04-9179 and 04-9007 (data not shown). These results agreed that microbial secondary metabolites are good resources for bioregulators. As microorganisms may produce the most diverse and unique, unprecedented, and sometimes very complicated compounds exhibiting excellent bioactivity and usually low toxicity, numerous and practically very important microbial secondary metabolites such as statins have been successfully used in the pharmacological fields. The screening of microbial secondary metabolite libraries is more efficient than any chemical approaches with regards to the discovery of structurally and mechanistically new active compounds. 14 Although a microbial secondary metabolite crude extract library was screened in the present work, the developed assay may be suitably applied to any chemical libraries, including combinatorial libraries, as it tolerated up to 0.5% DMSO ( Fig. 2A) . Once a drug candidate or lead compound is identified, it will be possible to use the combinatorial chemical libraries to provide more promising chances to discover more active, useful derivatives or analogues of the natural products.
Further analysis of the active compounds identified here, as well as those resulting from additional screening and identification, is expected to yield significant novel CLA-1 regulators. Availability of these small-molecule stimulators of CLA-1 in multiple chemical classes will be useful in further understanding the transcriptional regulation of the CLA-1/SR-BI gene in the liver, possibly via novel or known transcription factors, and may lead to the identification of drug candidates or lead compounds of new antiatherosclerosis agents.
